Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment

Movement Disorders

Volumn 32, Issue 2, 2017, Pages 193-202

  Slow, Elizabeth J ^a   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

crises; dopamine; dystonia; oculogyric

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; ORGANOPHOSPHATE; PENTAZOCINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; SALICYLIC ACID; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; ZIPRASIDONE;

6 PYRUVOLYLTETRAHYDROPTERIN SYNTHASE DEFICIENCY; ANTI NMDAR ENCEPHALITIS; AROMATIC LEVO AMINO ACID DECARBOXYLASE DEFICIENCY; CHEDIAK HIGASHI SYNDROME; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DOPAMINE METABOLISM; DOPAMINE TRANSPORTER DEFICIENCY; ENZYME DEFICIENCY; EPIDEMIC ENCEPHALITIS; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I DEFICIENCY; HUMAN; KUFOR RAKEB DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; OCULOGYRIC CRISIS; PARKINSONISM; PATHOGENESIS; PERRY SYNDROME; PHENOMENOLOGY; POSTENCEPHALITIC PARKINSONISM; PRIORITY JOURNAL; RAPID ONSET DYSTONIA PARKINSONISM; RETT SYNDROME; REVIEW; SEPIAPTERIN REDUCTASE DEFICIENCY; TYROSINE 3 MONOOXYGENASE DEFICIENCY; VESICULAR MONOAMINE TRANSPORTER 2 DEFICIENCY; DYSTONIC DISORDER; EYE MOVEMENT DISORDER;

DYSTONIC DISORDERS; HUMANS; OCULAR MOTILITY DISORDERS;

EID: 85013031408     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26910     Document Type: Review

References (95)

1. Vilensky J editor. Encephalitis Lethargica: During and After the Epidemic. New York: Oxford University Press; 2010:86-96.
2. Cheney G, Martins S. Postencephalitic paroxysmal oculogyric crises: report of cases. Cal West Med 1930;33:724-728.
3. Rail D, Scholtz C, Swash M. Post-encephalitic parkinsonism: current experience. J Neurol Neurosurg Psychiatry 1981;44:670-676.
4. Howard RS, Lees AJ. Encephalitis lethargica a report of four recent cases. Brain 1987;110:19-33.
5. Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66:704-709.
6. Kozinn PJ, Wiener H. Oculogyric crisis after a small dose of perphenazine. Case report of an eight-year-old girl. JAMA 1960;174:304-305.
7. Yoshida I, Sakaguchi Y, Matsuishi T, et al. Acute accidental overdosage of haloperidol in children. Acta Paediatr 1993;82:877-880.
8. Linazasoro G, Martí Massó JF, Olasagasti B. Acute dystonia induced by sulpiride. Clin Neuropharmacol 1991;14:463-464.
9. Khalid A, Nepal MK. Risperidone-induced oculogyric crisis. Indian J Psychiatry 2000;42:449-450.
10. Ramos AE, Shytle RD, Silver AA, et al. Ziprasidone-induced oculogyric crisis. J Am Acad Child Adolesc Psychiatry 2003;42:1013-1014.
11. Desarkar P, Das A, Sinha VK. Olanzapine-induced oculogyric crisis. Aust N Z J Psychiatry 2006;40:374.
12. Fountoulakis KN, Siamouli M, Kantartzis S, et al. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. Ann Pharmacother 2006;40:775-777.
13. Chakraborty R, Chatterjee A. Clozapine-induced oculogyric crises. Ann Pharmacother 2007;41:1916.
14. Koban Y, Ekinci M, Cagatay HH, et al. Oculogyric crisis in a patient taking metoclopramide. Clin Ophthalmol 2014;8:567-569.
15. Henry EV. Oculogyric crisis and carbamazepine. Arch Neurol 1980;37:326.
16. Veerapandiyan A, Gallentine WB, Winchester SA, et al. Oculogyric crises secondary to lamotrigine overdosage. Epilepsia 2011;52:e4-e6.
17. Burstein AH, Fullerton T. Oculogyric crisis possibly related to pentazocine. Ann Pharmacother 1993;27:874-876.
18. Chiaretti A, Schembri Wismayer D, Tortorolo L, et al. Salicylate intoxication using a skin ointment. Acta Paediatr 1997;86:330-331.
19. Hsieh BH, Deng JF, Ger J, et al. Acetylcholinesterase inhibition and the extrapyramidal syndrome: a review of the neurotoxicity of organophosphate. Neurotoxicology 2001;22:423-427.
20. Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit Care Med 2002;30:473-476.
21. Ritter MJ, Goodman BP, Sprung J, et al. Ondansetron-induced multifocal encephalopathy. Mayo Clin Proc 2003;78:1150-1152.
22. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111:1275-1279.
23. Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984;34:688-692.
24. Janik P, Figura M. Tetrabenazine-induced oculogyric crisis—a rare complication in the treatment of Gilles de la Tourette syndrome. Neuropsychiatr Dis Treat 2016;12:497-499.
25. Reeves AL, So EL, Sharbrough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-990.
26. FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology 1989;39:1434-1437.
27. Sachdev P. Tardive and chronically recurrent oculogyric crises. Mov Disord 1993;8:93-97.
28. Praharaj SK, Jana AK, Sarkar S, Sinha VK. Olanzapine-induced tardive oculogyric crisis. J Clin Psychopharmacol 2009;29:604-606.
29. Ghosh S, Dhrubajyoti B, Bhattacharya A, et al. Tardive oculogyric crisis associated with quetiapine use. J Clin Psychopharmacol 2013;33:266.
30. Mendhekar DN, Lohia D, Kataria P. Tardive oculogyric crisis associated with amisulpride monotherapy. J Postgrad Med 2010;56:305-306.
31. Uzun O, Doruk A. Tardive oculogyric crisis during treatment with clozapine: report of three cases. Clin Drug Investig 2007;27:861-864.
32. Gupta R, Balhara Y. Antipsychotic induced chronic recurrent oculogyric crisis in a patient with obsessive compulsive disorder. Psychopharmacology 2014;231:3065-3066.
33. Kurian MA, Gissen P, Smith M, et al. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011;10:721-733.
34. Brun L, Ngu LH, Keng WT, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 2010;75:64-71.
35. Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012;71:520-530.
36. Willemsen MA, Verbeek MM, Kamsteeg EJ et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010;133:1810-1822.
37. Rilstone JJ, Alkhater RA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 2013;368:543-550.
38. Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 2011;10:54-62.
39. Leuzzi V, Carducci CA, Carducci CL et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 2010;77:249-257.
40. Wijemanne S, Jankovic J. Dopa-responsive dystonia—clinical and genetic heterogeneity. Nat Rev Neurol 2015;11:414-424.
41. Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 2014;137:1107-1119.
42. Lai S-C, Jung S-M, Grattan-Smith P, et al. Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. Mov Disord 2010;25:1274-1279.
43. Dehay B, Ramirez A, Martinez-Vicente M, et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 2012;109:9611-9616.
44. Williams DR, Hadeed A, al-Din AS, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005;20:1264-1271.
45. Erro R, Hersheson J, Ganos C, et al. H-ABC syndrome and DYT4: variable expressivity or pleiotropy of TUBB4 mutations? Mov Disord 2015;30:828-833.
46. Zaremba J, Mierzewska H, Lysiak Z, et al. Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13. Mov Disord 2004;19:1506-1510.
47. Sweney MT, Newcomb TM, Swoboda KJ. The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, alternating hemiplegia of childhood, rapid-onset dystonia-parkinsonism, CAPOS and beyond. Pediatr Neurol 2015;52:56-64.
48. De Giorgis V, Varesio C, Baldassari C, et al. Atypical manifestations in Glut1 deficiency syndrome. J Child Neurol 2016;31:1174-1180.
49. Chung EJ, Hwang JH, Lee MJ, et al. Expansion of the clinicopathological and mutational spectrum of Perry syndrome. Parkinsonism Relat Disord 2014;20:388-393.
50. Uyama E, Hirano T, Ito K, et al. Adult Chédiak-Higashi syndrome presenting as parkinsonism and dementia. Acta Neurol Scand 1994;89:175-183.
51. FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord 1990;5:195-202.
52. Suzuki H, Matsuzaka T, Hirayama Y et al. Rett's syndrome: progression of symptoms from infancy to childhood. J Child Neurol 1986;1:137-141.
53. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
54. Lemke JR, Geider K, Helbig KL, et al. Delineating the GRIN1 phenotypic spectrum: a distinct genetic NMDA receptor encephalopathy. Neurology 2016;86:2171-2178.
55. Liu GT, Carrazana EJ, Macklis JD, et al. Delayed oculogyric crises associated with striatocapsular infarction. J Clin Neuroophthalmol 1991;11:198-201.
56. Marca Della G, Frisullo G, Vollono C, et al. Oculogyric crisis in a midbrain lesion. Arch Neurol 2011;68:390-391.
57. Lee MS, Kim YD, Lyoo CH. Oculogyric crisis as an initial manifestation of Wilson's disease. Neurology 1999;12:1714-1715.
58. Matsumura K, Sakuta M. Oculogyric crisis in acute herpetic brainstem encephalitis. J Neurol Neurosurg Psychiatry 1987;50:365-366.
59. Kalita J, Misra UK. Markedly severe dystonia in Japanese encephalitis. Mov Disord 2000;15:1168-1172.
60. Scarmeas N, Eidelberg D, Frucht SJ, et al. Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism. Mov Disord 2001;16:353-355.
61. Bennett JL, Galetta SL, Frohman LP, et al. Neuro-ophthalmologic manifestations of a paraneoplastic syndrome and testicular carcinoma. Neurology 1999;52:864-867.
62. Virmani T, Thenganatt MA, Goldman JS, et al. Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia. Parkinsonism Relat Disord 2014;20:245-247.
63. Antunes NL, Small TN, George D, et al. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 1999;20:241-243.
64. Zupanc ML, Chun RW, Gilbert-Barness EF. Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. Pediatr Neurol 1990;6:349-352.
65. Kamida T, Maruyama T, Fujiki M, et al. Total callosotomy for a case of lissencephaly presenting with West syndrome and generalized seizures. Childs Nerv Syst 2005;21:1056-1060.
66. Kis B, Hedrich K, Kann M, et al. Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications. Neurology 2005;65:761.
67. Barton JJ, Cox TA, Calne DA. Involuntary ocular deviations and generalized dystonia in multiple sclerosis. A case report. J Neuroophthalmol 1994;14:160-162.
68. Ferrara J, Gupta D, Foster E, et al. Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration. Mov Disord 2008;23:875-878.
69. Salmina C, Taddeo I, Falesi M, et al. Paroxysmal tonic upgaze in normal children: a case series and a review of the literature. Eur J Paediatr Neurol 2012;16:683-687.
70. Hills LB, Masri A, Konno K, et al. Deletions in GRID2 lead to a recessive syndrome of cerebellar ataxia and tonic upgaze in humans. Neurology 2013;81:1378-1386.
71. Skalicky SE, Billson FA. Benign paroxysmal tonic upgaze of childhood in a hypotonic infant with Beckwith-Wiedemann syndrome. Clin Experiment Ophthalmol 2008;36:291-292.
72. Blumkin L, Lev D, Watemberg N, et al. Hypomyelinating leukoencephalopathy with paroxysmal tonic upgaze and absence of psychomotor development. Mov Disord 2007;22:226-230.
73. Roubertie A, Echenne B, Leydet J, et al. Benign paroxysmal tonic upgaze, benign paroxysmal torticollis, episodic ataxia and CACNA1A mutation in a family. J Neurol 2008;255:1600-1602.
74. Verrotti A, Di Marco G, la Torre R, et al. Paroxysmal tonic upgaze of childhood and childhood absence epilepsy. Eur J Pediatr Neurol 2010;14:93-96.
75. LeWitt PA. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. Mov Disord 1998;13:731-734.
76. Mehler MF. The clinical spectrum of ocular bobbing and ocular dipping. J Neurol Neurosurg Psychiatry 1988;51:725-727.
77. Frankel M, Cummings JL. Neuro-opthalmic abnormalities in Tourette's syndrome: Functional and anatomic implications. Neurology 1984;34:359-361.
78. Baizabal-Carvallo JF, Jankovic J. Psychogenic ophthalmologic movement disorders. J Neuropsychiatry Clin Neurosci 2016;28:195-198.
79. Berger JR, Vilensky JA. Encephalitis lethargica (von Economo's encephalitis). Handb Clin Neurol 2014;123:745-761.
80. Hoffman HL. Effect of benzedrine on the oculogyric crises of parkinsonism. Br Med J 1941;1:816-818.
81. Sacks OW, Kohl M. L-dopa and oculogyric crises. Lancet 1970;2:215-216.
82. Basselin M, Chang L, Chen M, et al. Chronic carbamazepine administration attenuates dopamine D2-like receptor-initiated signaling via arachidonic acid in rat brain. Neurochem Res 2008;33:1373-1383.
83. Southam E, Kirkby D, Higgins GA, et al. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 1998;25:19-24.
84. Brashear A, Butler IJ, Hyland K, et al. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. Ann Neurol 1998;43:521-526.
85. Poceta JS, Parsons L, Engelland S, et al. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med 2009;10:129-133.
86. Mazurek MF, Rosebush PI. Circadian pattern of acute, neuroleptic-induced dystonic reactions. Am J Psychiatry 1996;153:708-710.
87. Furuta N, Furuta M, Makioka K, et al. Parkinson's disease presenting with oculogyric crisis in the off period. Intern Med 2014;53:793-795.
88. Lu M, Schultz L, Auiinger P, et al. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res 2011;1408:88-97.
89. Ishibashi K, Kanemaru K, Saito Y, et al. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. Acta Neurol Scand. 2010;122:46-51.
90. de Belleroche JS, Neal MJ. The contrasting effects of neuroleptics on transmitter release from the nucleus accumbens and corpus striatum. Neuropharmacology 1982;21:529-537.
91. Horiguchi J, Inami Y. Effect of clonazepam on neuroleptic-induced oculogyric crisis. Acta Psychiatr Scand 1989;80:521-523.
92. Hyland K, Surtees RA, Rodeck C, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992;42:1980-1988.
93. Meldrum BS, Anlezark GM, Marsden CD. Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain 1977;100:313-326.
94. Leigh RJ, Foley JM, Remler BF, et al. Oculogyric crisis: a syndrome of thought disorder and ocular deviation. Ann Neurol 1987;22:13-17.
95. Samaco RC, Mandel-Brehm C, Chao HT, et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci U S A 2009;106:21966-21971.